Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays
TOKYO, Aug 24, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics (“C2N”) that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer’s disease (AD),... » read more